hs-CRP和PPARγ在动脉粥样硬化患者的临床应用

The clinical significance of atherosclerosis danger degree in patient with atherosclerosis level high-sensitivity C-reactive protein,peroxisome prolife activated receptor gamma

目的探讨动脉粥样硬化患者血清高敏C反应蛋白及单核细胞过氧化物酶增殖体激活型受体γ水平变化在动脉粥样硬化危险程度中的临床意义。方法采用酶联免疫法(ELSA)将动脉粥样硬化组134例患者与正常对照组45例进行比较。结果动脉粥样硬化患者血清hs-CRP浓度显著高于正常对照组,而PPARγ浓度显著低于正常对照组(P<0.01);急性冠脉综合征中急性心肌梗塞组hs-CRP水平较不稳定型心绞痛组升高(P<0.01),PPARγ水平明显低于不稳定型心绞痛组;hs-CRP与PPARr负相关(P<0.01)。结论hs-CRP和PPARγ对动脉粥样硬化有一定的影响,且随动脉粥样硬化危险程度不同而变化,在临床上可为动脉粥样硬化危险程度提供依据。

Objective To explore patient with atheroselerosis level of high-sensitivity C-reactive protein, peroxisome prolife activated receptor gamma in atheroselerosis danger stratification significance. Methods 45 normal persons and 134 patients with ACS were investigated usual examine TnI,TnT ,CK-MB ,TC ,HDL-C ELLSA：measure eoneeneration of Hs- CRP, PPARγ. Results Patients with atheroselerosis had higher level of serum hs-CRP 8.08±0.52 （mg/L） versus 2.99±0A6（mg/ L） respectively （P〈0.01）, and lower PPARγ hat in patients with normal persoms 1.16±0.44 versus 5.94±0.55 respeetirely （P〈 0.01）, Serum level of hs-CRP in patient with AMI was higher than that inpatient with UA （16.08±0.87 versus 5.22±0.73（mg/L） respectiely （P〈0.01）, Serum level of PPARγ in patients with AMI was lower than that in patients with unstable angina （0.52± 0.43 versus 3.14±0.89 respectively, P〈0.01）.PPARγ expression in monoeyte increased and serum hs-CRP decreased after treatment. The effect of atorvastation 40mg/d on PPARγ and hs-CRP was moro effective than that of atorvastation 10mg/d（PPARγ3.38±0.13 versus 0.52±0.03 respectively,P〈0.01 ;hs-CRP11.46±2,15 versus 1.01 ±2.26mg/L respectively,P〈0.01）. Conclusion hs-CRP,PPAR＇y may paly aeertain rolein the occurrence and development of Atheroselerosis. Therefore levels of serum hs- CRP, PPAR＇y may be used as danger degree of atheroselerosis.